ArticleClinical cancer research : an official journal of the American Association for Cancer Research2022

A Phase I, Open-Label, Dose-Escalation Study of the OX40 Agonist Ivuxolimab in Patients with Locally Advanced or Metastatic Cancers.

Adi Diab et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.